Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Dr Reddy's, Zydus Lifesciences,... Feb 19, 2025 19:23 Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue ...

Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Cipla share price: In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib capsules in 50 mg, 150 mg, and 200 mg strengths. The oral ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Return on investment - most recent fiscal year 16.16 ...

Umang Vohra to Nimura: "In the case of tariff barriers, generics companies are likely to be more selective, focusing on high-value opportunities including 'first to file'." The Managing Director ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla Limited on Tuesday announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% ...

Cipla has received final approval from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for Nilotinib Capsules in 50 mg, 150 mg, and 200 mg dosages. Nilotinib is indicated ...

Maruti Swift price in Jaipur start at ₹ 6.49 Lakh. The lowest price model is Maruti Swift LXi and the top model price is Maruti Swift ZXi Plus AMT DT priced at ₹ 9.64 Lakh. Visit your nearest ...